Anti-CLK2 Antibody Picoband® Fluoro488 Conjugated

Dual specificity protein kinase CLK2 is an enzyme that in humans is encoded by the CLK2 gene. It is mapped to 1q22. This gene encodes a dual specificity protein kinase that phosphorylates serine/threonine and tyrosine-containing substrates. Activity of this protein regulates serine- and arginine-rich (SR) proteins of the spliceosomal complex, thereby influencing alternative transcript splicing. Chromosomal translocations have been characterized between this locus and the PAFAH1B3 (platelet-activating factor acetylhydrolase 1b, catalytic subunit 3 (29kDa) ) gene on chromosome 19, resulting in the production of a fusion protein. Note that this gene is distinct from the TELO2 gene (GeneID:9894), which shares the CLK2 alias, but encodes a protein that is involved in telomere length regulation. There is a pseudogene for this gene on chromosome 7. Alternative splicing results in multiple transcript variants.

Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex. May be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing and can cause redistribution of SR proteins from speckles to a diffuse nucleoplasmic distribution. Acts as a suppressor of hepatic gluconeogenesis and glucose output by repressing PPARGC1A transcriptional activity on gluconeogenic genes via its phosphorylation. Phosphorylates PPP2R5B thereby stimulating the assembly of PP2A phosphatase with the PPP2R5B-AKT1 complex leading to dephosphorylation of AKT1. Phosphorylates: PTPN1, SRSF1 and SRSF3. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Phosphorylates PAGE4 at several serine and threonine residues and this phosphorylation attenuates the ability of PAGE4 to potentiate the transcriptional activator activity of JUN.

1. Bidinosti, M., Botta, P., Kruttner, S., Proenca, C. C., Stoehr, N., Bernhard, M., Fruh, I., Mueller, M., Bonenfant, D., Voshol, H., Carbone, W., Neal, S. J., McTighe, S. M., Roma, G., Dolmetsch, R. E., Porter, J. A., Caroni, P., Bouwmeester, T., Luthi, A., Galimberti, I. CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency. Science 351: 1199-1203, 2016. 2. Hanes, J., von der Kammer, H., Klaudiny, J., Scheit, K. H. Characterization by cDNA cloning of two new human protein kinases: evidence by sequence comparison of a new family of mammalian protein kinases. J. Molec. Biol. 244: 665-672, 1994. 3. Nothwang, H. G., Kim, H. G., Aoki, J., Geisterfer, M., Kubart, S., Wegner, R. D., van Moers, A., Ashworth, L. K., Haaf, T., Bell, J., Arai, H., Tommerup, N., Ropers, H. H., Wirth, J. Functional hemizygosity of PAFAH1B3 due to a PAFAH1B3-CLK2 fusion gene in a female with mental retardation, ataxia and atrophy of the brain. Hum. Molec. Genet. 10: 797-806, 2001.